168 related articles for article (PubMed ID: 38578203)
1. IL-2-mediated hepatotoxicity: knowledge gap identification based on the irAOP concept.
Roser LA; Sakellariou C; Lindstedt M; Neuhaus V; Dehmel S; Sommer C; Raasch M; Flandre T; Roesener S; Hewitt P; Parnham MJ; Sewald K; Schiffmann S
J Immunotoxicol; 2024 Dec; 21(1):2332177. PubMed ID: 38578203
[TBL] [Abstract][Full Text] [Related]
2. Immuno-inflammatory
Roser LA; Luckhardt S; Ziegler N; Thomas D; Wagner PV; Damm G; Scheffschick A; Hewitt P; Parnham MJ; Schiffmann S
Front Immunol; 2023; 14():1275368. PubMed ID: 38045689
[TBL] [Abstract][Full Text] [Related]
3. Idiosyncratic drug hepatotoxicity.
Kaplowitz N
Nat Rev Drug Discov; 2005 Jun; 4(6):489-99. PubMed ID: 15931258
[TBL] [Abstract][Full Text] [Related]
4. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
Prandota J
Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
[TBL] [Abstract][Full Text] [Related]
5. Safety data and withdrawal of hepatotoxic drugs.
Babai S; Auclert L; Le-Louët H
Therapie; 2021; 76(6):715-723. PubMed ID: 29609830
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages.
Giri S; Nieber K; Bader A
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):895-917. PubMed ID: 20367107
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
Wang H; Yang H; Zhou X; Zhang X
Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
[TBL] [Abstract][Full Text] [Related]
8. The hepatotoxicity assessment of micro/nanoplastics: A preliminary study to apply the adverse outcome pathways.
Ge Y; Yang S; Zhang T; Wan X; Zhu Y; Yang F; Yin L; Pu Y; Liang G
Sci Total Environ; 2023 Dec; 902():165659. PubMed ID: 37517720
[TBL] [Abstract][Full Text] [Related]
9. Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
Thompson RA; Isin EM; Ogese MO; Mettetal JT; Williams DP
Chem Res Toxicol; 2016 Apr; 29(4):505-33. PubMed ID: 26735163
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of potential hepatotoxicity induced by drugs.
Gómez-Lechón MJ; Lahoz A; Gombau L; Castell JV; Donato MT
Curr Pharm Des; 2010 Jun; 16(17):1963-77. PubMed ID: 20236064
[TBL] [Abstract][Full Text] [Related]
11. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
12. An adverse outcome pathway-based approach to assess aurantio-obtusin-induced hepatotoxicity.
Hu M; Zhong Y; Liu J; Zheng S; Lin L; Lin X; Liang B; Huang Y; Xian H; Li Z; Zhang B; Wang B; Meng H; Du J; Ye R; Lu Z; Yang X; Yang X; Huang Z
Toxicology; 2022 Aug; 478():153293. PubMed ID: 35995123
[TBL] [Abstract][Full Text] [Related]
13.
Mirahmad M; Sabourian R; Mahdavi M; Larijani B; Safavi M
Drug Metab Rev; 2022 May; 54(2):161-193. PubMed ID: 35403528
[TBL] [Abstract][Full Text] [Related]
14. Metabonomics for discovering biomarkers of hepatotoxicity and nephrotoxicity.
Zhang A; Sun H; Wang P; Han Y; Wang X
Pharmazie; 2012 Feb; 67(2):99-105. PubMed ID: 22512077
[TBL] [Abstract][Full Text] [Related]
15. Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury.
Goldring C; Antoine DJ; Bonner F; Crozier J; Denning C; Fontana RJ; Hanley NA; Hay DC; Ingelman-Sundberg M; Juhila S; Kitteringham N; Silva-Lima B; Norris A; Pridgeon C; Ross JA; Young RS; Tagle D; Tornesi B; van de Water B; Weaver RJ; Zhang F; Park BK
Hepatology; 2017 Feb; 65(2):710-721. PubMed ID: 27775817
[TBL] [Abstract][Full Text] [Related]
16. Herbal hepatotoxicity.
Stickel F; Patsenker E; Schuppan D
J Hepatol; 2005 Nov; 43(5):901-10. PubMed ID: 16171893
[No Abstract] [Full Text] [Related]
17. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury.
Proctor WR; Foster AJ; Vogt J; Summers C; Middleton B; Pilling MA; Shienson D; Kijanska M; Ströbel S; Kelm JM; Morgan P; Messner S; Williams D
Arch Toxicol; 2017 Aug; 91(8):2849-2863. PubMed ID: 28612260
[TBL] [Abstract][Full Text] [Related]
18. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science.
Antoine DJ; Williams DP; Park BK
Expert Opin Drug Metab Toxicol; 2008 Nov; 4(11):1415-27. PubMed ID: 18950283
[TBL] [Abstract][Full Text] [Related]
19. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.
Cosgrove BD; King BM; Hasan MA; Alexopoulos LG; Farazi PA; Hendriks BS; Griffith LG; Sorger PK; Tidor B; Xu JJ; Lauffenburger DA
Toxicol Appl Pharmacol; 2009 Jun; 237(3):317-30. PubMed ID: 19362101
[TBL] [Abstract][Full Text] [Related]
20. An expert system approach to the assessment of hepatotoxic potential.
Marchant CA; Fisk L; Note RR; Patel ML; Suárez D
Chem Biodivers; 2009 Nov; 6(11):2107-14. PubMed ID: 19937847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
